

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently amended). A topically-applicable photodynamic pharmaceutical composition consisting of a halogenated xanthene as the photoactive component, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, and wherein said halogenated xanthene is present in a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v, said pharmaceutical composition to be photoactivated 1 hour or less ~~than 24 hours~~ following application, and wherein said pharmaceutical composition is useful for treatment of diseases of human and animal tissue.

Claim 2 (Canceled).

Claim 3 (Previously presented). The pharmaceutical composition of Claim 1 wherein said halogenated xanthene is Rose Bengal.

Claim 4-6 (Canceled).

Claim 7 (Previously presented). The pharmaceutical composition of Claim 1 wherein said

pharmaceutical composition is formulated in a delivery vehicle selected from the group consisting of a liquid, a semisolid, a solid and an aerosol.

Claim 8 (Previously presented). The pharmaceutical composition of Claim 7 wherein said vehicle is selected from the group consisting of an aqueous suspension, a non-aqueous suspension, a nanoparticulate suspension, a solution, a cream, an ointment, a gel, a syrup, a suppository and a micro-droplet spray.

Claim 9 (Currently amended). The pharmaceutical composition of Claim 1 wherein said halogenated xanthene is in a delivery vehicle that includes one or more adjuvants selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers, electrolytes, ~~tissue penetrating agents~~ and tissue softening agents.

Claim 10 (Previously presented). The pharmaceutical composition of Claim 1 wherein said pharmaceutical composition is useful for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.

Claim 11 (Canceled).

Claim 12 (Previously presented). The pharmaceutical composition of Claim 1 wherein said pharmaceutical composition is photoactivated using light having a wavelength of between approximately 500 nm and 600 nm.

Claim 13 (Currently amended). Use of a halogenated xanthene as the active component in the preparation of a topical photodynamic medicament for treatment of human and animal tissue using photodynamic therapy, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, said halogenated xanthene being present in a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v, and wherein said medicament is photoactivated 1 hour or less ~~than 24 hours~~ following administration.

Claim 14 (Previously presented). The use of Claim 13 wherein said medicament is useful for the treatment of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.

Claim 15 (Previously presented). The use of Claim 13 wherein said halogenated xanthene is Rose Bengal.

Claim 16 (Previously presented). The use of Claim 13 wherein said medicament is photoactivated using light having a wavelength of between approximately 500 nm and 600 nm.

Claim 17 (Currently amended). Use of a halogenated xanthene comprising:
topically administering a therapeutically effective amount of the halogenated xanthene as the photoactive agent, present in a pharmaceutical composition in a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v, to or proximate to human or animal tissue and photoactivating the halogenated xanthene present within or proximate to said tissue within 1 hour or less than 24 hours following administration, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein.

Claim 18 (Previously presented). The use of Claim 17 wherein said halogenated xanthene is Rose Bengal.

Claim 19 (Previously presented). The use of Claim 17 wherein said halogenated xanthene is photoactivated with light having a wavelength of between approximately 500 nm and 600 nm.

Claim 20 (Canceled).

Claim 21 (Currently amended). A photodynamic pharmaceutical composition for topical administration consisting of a halogenated xanthene as the photoactive component for treatment using photodynamic therapy within 1 hour or less than 24 hours following administration, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, and wherein said halogenated xanthene is present in a concentration of greater than approximately 0.0001% w/v to less than approximately 1%w/v.

Claim 22 (Canceled).

Claim 23 (Previously presented). The pharmaceutical composition of Claim 21 wherein said halogenated xanthene is Rose Bengal.

Claim 24-26 (Canceled).

Claim 27 (Previously presented). The pharmaceutical composition of Claim 21 wherein said pharmaceutical composition is formulated in a delivery vehicle selected from the group consisting

of a liquid, a semisolid, a solid and an aerosol.

Claim 28 (Previously presented). The pharmaceutical composition of Claim 27 wherein said vehicle is selected from the group consisting of an aqueous suspension, a non-aqueous suspension, a nanoparticulate suspension, a solution, a cream, an ointment, a gel, a syrup, a suppository and a micro-droplet spray.

Claim 29 (Currently amended). The pharmaceutical composition of Claim 21 wherein said halogenated xanthene is in a delivery vehicle that includes one or more adjuvants selected from the group consisting of builders, stabilizers, emulsifiers, dispersants, preservatives, buffers, electrolytes, ~~tissue penetrating agents~~ and tissue softening agents.

Claim 30 (Previously presented). The pharmaceutical composition of Claim 21 wherein said photodynamic therapy uses activating light having a wavelength of between approximately 500 nm and 600 nm.

Claim 31 (Canceled).

Claim 32 (Currently amended). A method of treating diseased tissue comprising:
topically applying a photodynamic medicament consisting of a halogenated xanthene as the photoactive component to or proximate to diseased human or animal tissue, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of

Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, said halogenated xanthene being present in said medicament at a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v; and

illuminating said human or animal tissue with light within 1 hour or less ~~than 24 hours~~ following said applying to photoactivate said halogenated xanthene present within or proximate to said tissue.

Claim 33 (Previously presented). The method of Claim 32 wherein said diseased human or animal tissue comprises the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tracts and related organs, other internal and external tissue surfaces, tissue surfaces exposed during surgery, and tissue with microbial or parasitic infection.

Claim 34 (Previously presented). The method of Claim 32 wherein said step of illuminating uses light having a wavelength of between approximately 500 nm and 600 nm.

Claim 35 (Canceled).

Claim 36 (Currently amended). A topically-applicable photodynamic medicament consisting of a halogenated xanthene as the photoactive component, wherein said halogenated xanthene is a

compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, said halogenated xanthene being present in said medicament at a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v, and, wherein such topically-applicable photodynamic medicament is for photodynamic treatment of human and animal tissue using photoactivation within 1 hour or less than 24 hours following application.

Claim 37 (Currently amended). A topically-applicable photodynamic medicament consisting of a halogenated xanthene as the active component, wherein said halogenated xanthene is a compound selected from the group consisting of the dibasic salts of Erythrosin B; Phloxine B; Rose Bengal; 4,5,6,7-Tetrabromoerythrosin; Mono-, Di-, or Tribromoerythrosin; Mono-, Di-, or Trichloroerythrosin; Mono-, Di-, or Trifluoroerythrosin; 2',7'-Dichloro-4,5,6,7-Tetrafluorofluorescein; 2',4,5,6,7,7'-Hexafluorofluorescein; and 4,5,6,7-Tetrafluorofluorescein, said halogenated xanthene being present in said medicament at a concentration of greater than approximately 0.0001% w/v to less than approximately 1% w/v, and wherein such topically-applicable photodynamic medicament is for photodynamic treatment, to be photoactivated within 1 hour or less than 24 hours following application, of indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tracts and related organs, diseases of other internal and external tissue surfaces, tissue surfaces exposed during surgery, and microbial or parasitic infection.